These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 794497)

  • 21. Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice.
    Kawase I; Niitani H; Saijo N; Sasaki H; Morita T
    Gan; 1978 Aug; 69(4):493-7. PubMed ID: 101414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hybrid resistance to EL-4 lymphoma cells. I. Characterization of natural killer cells that lyse EL-4 cells and their distinction from marrow-dependent natural killer cells.
    Kumar V; Luevano E; Bennett M
    J Exp Med; 1979 Sep; 150(3):531-47. PubMed ID: 383877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
    Mathé G; Halle-Pannenko O; Bourut C
    Natl Cancer Inst Monogr; 1973 Dec; 39():107-13. PubMed ID: 4150738
    [No Abstract]   [Full Text] [Related]  

  • 24. Nonspecific resistance to tumor allograft.
    Rejthar A; Wotke J; Rejtharová A; Jasková J
    Neoplasma; 1975; 22(3):273-8. PubMed ID: 1099469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of bacille Calmette-Guérin on the immune response of BALB/c mice to a tumor allograft.
    Treagan L; Chen TH; Rambo O; Elberg SS
    J Infect Dis; 1979 Oct; 140(4):541-5. PubMed ID: 117062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice.
    Vyakarnam A; Lachmann PJ; Sikora K
    Immunology; 1981 Feb; 42(2):337-48. PubMed ID: 6161889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of tumor resistance with BCG-associated tumor antigen.
    Crum ED; McGregor DD
    Int J Cancer; 1977 Nov; 20(5):805-12. PubMed ID: 200576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Xenogeneic cellular immune responses and the control of microscopic tumor. A model.
    Smith TJ; Sugarbaker PH
    Oncology; 1982; 39(2):93-100. PubMed ID: 6977754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Passive transfer of systemic tumor immunity with cells generated in vitro by a secondary immune response to a syngeneic rat gross virus-induced lymphoma.
    Bernstein ID
    J Immunol; 1977 Jan; 118(1):122-8. PubMed ID: 830744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation of the antitumor effect of adoptive immunotherapy by in vivo sensitization of EL-4 lymphoma and pre-treatment with sizofiran.
    Kano Y; Kakuta H; Hashimoto J
    Biotherapy; 1998; 11(1):1-6. PubMed ID: 9617459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor immunity induced by BCG-tumor cell mixtures in syngeneic mice.
    Tokunaga T; Kataoka T; Nakamura RM; Yamamoto S; Tanaka T
    Jpn J Med Sci Biol; 1973 Apr; 26(2):71-85. PubMed ID: 4585343
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of BCG on cell-mediated cytotoxicity and serum blocking factor during growth of rat hepatoma.
    Embleton MJ
    Br J Cancer; 1976 Jun; 33(6):584-92. PubMed ID: 181041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced response to chemoimmunotherapy and immunoprophylaxis with the use of tumor-associated antigens with a lipophilic agent.
    Prager MD; Gordon WC
    Cancer Res; 1978 Jul; 38(7):2052-7. PubMed ID: 657141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of modified tumor cells in syngenic hosts.
    Prager MD; Gordon WC; Baechtel FS
    Ann N Y Acad Sci; 1976; 276():61-74. PubMed ID: 1071980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin.
    Dubois JB; Serrou B
    Cancer Res; 1976 May; 36(5):1731-4. PubMed ID: 773530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo natural antitumor resistance against murine EL-4 lymphoma cells in lethally irradiated syngeneic C57Bl/6 mice.
    Iorio AM; Neri M; Bonmassar E; Titti F; Rossi GB
    Cell Immunol; 1987 Aug; 108(1):85-96. PubMed ID: 3607887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A stable form of delayed-type hypersensitivity.
    Lagrange PH; Mackaness GB
    J Exp Med; 1975 Jan; 141(1):82-96. PubMed ID: 1090700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoprophylaxis and treatment of leukemia in AKR mice: repetitive use of BCG.
    Mardiney MR; Ungaro PC; Drake WP
    Natl Cancer Inst Monogr; 1973 Dec; 39():89-90. PubMed ID: 4595329
    [No Abstract]   [Full Text] [Related]  

  • 40. Adjuvant and antitumor activities of Nocardia cell-wall skeletons.
    Azuma I; Taniyama T; Yamawaki M; Sugimura K; Yamamura Y
    Gan; 1976 Oct; 67(5):733-6. PubMed ID: 797626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.